The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer

B Nguyen; M Marion; R Salgado; D Venet; P Vuylsteke; L Polastro; H Wieldiers; P Simon; G Lindeman; D Larsimont; G Van den Eynden; C Velghe; F Rothe; S Garaud; S Michiels; K Willard-Gallo; HA Azim; S Loi; M Piccart; C Sotiriou

Conference Proceedings

The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer

B Nguyen, M Marion, R Salgado, D Venet, P Vuylsteke, L Polastro, H Wieldiers, P Simon, G Lindeman, D Larsimont, G Van den Eynden, C Velghe, F Rothe, S Garaud, S Michiels, K Willard-Gallo, HA Azim, S Loi, M Piccart, C Sotiriou

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019

DOI: 10.1158/1538-7445.SABCS18-PD5-06

Abstract

Abstract Background Breast cancer (BC) in young women has unique biology and poor prognosis. Previous reports suggest that they often express RANKL, which was also shown to play a role in mammary tumorigenesis and various immune processes. Here, we present the primary results of D-BEYOND, a window study investigating the biological activity of the RANKL inhibitor; denosumab in pre-menopausal BC patients. Methods D-BEYOND is a prospective, phase Iia, single-arm, multicenter study assessing the effect of denosumab on BC biology in premenopausal women with early BC (NCT01864798). Patients received two subcutaneous injections of denosum..

View full abstract